Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events

  • Technology appraisal guidance
  • TA210
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by Liverpool Reviews and Implementation Group:

  • Greenhalgh J, Saborido CM, Bagust A et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal 90), April 2010

  • Greenhalgh J, Saborido CM, Bagust A et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal 90) addendum, April 2010

  • Greenhalgh J, Saborido CM, Bagust A et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal 90) addendum 2, May 2010

  • Greenhalgh J, Saborido CM, Bagust A et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal 90) addendum 3, June 2010

  • Greenhalgh J, Saborido CM, Bagust A et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal 90) addendum 4, June 2010

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I, II and III were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I) Manufacturers/sponsors:

  • Boehringer Ingelheim

  • Bristol-Myers Squibb

  • Sanofi-Aventis

II) Professional/specialist and patient/carer groups:

  • Anticoagulation Europe (ACE)

  • Diabetes UK

  • Heart Care Partnership (UK)

  • HEART UK

  • Insulin Dependent Diabetes Trust (IDDT)

  • The Stroke Association

  • Association of British Neurologists

  • British Association of Stroke Physicians

  • British Cardiovascular Intervention Society (BCIS)

  • British Cardiovascular Society

  • British Heart Foundation

  • Royal College

  • Royal College of Physicians Cardiology Committee

  • The Vascular Society

III) Other consultees:

  • Department of Health

  • Welsh Assembly Government

IV) Commentator organisations (without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Medicines and Healthcare products Regulatory Agency

  • NHS Quality Improvement Scotland

  • Bayer (aspirin)

  • Galpharm International (aspirin)

  • Liverpool Reviews and Implementation Group, University of Liverpool

  • National Institute for Health Research Health Technology Assessment Programme

C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal guidance 90) by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Russell Smith, Consultant Cardiologist, nominated by British Cardiovascular Society – clinical specialist

  • Professor Thompson Robinson, Professor of Stroke Medicine, nominated by British Association of Stroke Physicians – clinical specialist

  • David Gerald MBE, Immediate Past President, nominated by Heart Care Partnership UK – patient expert

  • Dr Rob Ryckborst, nominated by Insulin Dependent Diabetes Trust – patient expert

D. Representatives from the following manufacturers/sponsors attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Boehringer Ingelheim

  • Bristol-Myers Squibb Pharmaceuticals Ltd

  • Sanofi-Aventis